AI assistant
Sending…
Traws Pharma, Inc. — Director's Dealing 2021
Aug 5, 2021
35199_dirs_2021-08-04_84ef223c-3038-46cc-aa41-497e68f9ba48.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2021-08-02
Reporting Person: Fruchtman Steven M (Director, President, Chief Executive Off)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-02 | Stock Option (right to purchase) | $5.19 | A | 113000 | Acquired | 2031-08-02 | Common stock (113000) | Direct |
| 2021-08-02 | Restricted Stock Unit | $ | A | 37700 | Acquired | Common stock (37700) | Direct |
Footnotes
F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
F2: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.
F3: Each restricted stock unit is convertible into one share of common stock.
More from Traws Pharma, Inc.
Annual Report
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 26
Share Issue/Capital Change
2026
May 22
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 8